Rare Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have signed a consent form agreeing to take part
- You are 18 years old or older
- You are covered by a social security (health insurance) scheme
- (For the "cases" group) You have been referred for joint inflammation (arthritis) or inflammation of a fluid-filled sac near a joint (bursitis) linked to a rare autoimmune disease or a side effect of medication, confirmed by ultrasound scan
- (For the "control" group – arthritis) You have joint inflammation confirmed by ultrasound, and you have been diagnosed with rheumatoid arthritis, a form of spondyloarthritis, psoriatic arthritis, or reactive arthritis according to recognised medical criteria
- (For the "control" group – bursitis) You have inflammation of a fluid-filled sac near a joint confirmed by ultrasound, and you meet the recognised criteria for a condition called polymyalgia rheumatica
Who may not be able to join:
- You are under a legal protection order or are unable to give your own consent
- You are pregnant or currently breastfeeding
- You are taking blood-thinning medications such as warfarin (Coumadin), fluindione, apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban, or heparin at treatment doses
- There is a reason you cannot safely have a local procedure on the joint, such as swelling caused by lymph drainage problems near the joint, an open wound at the joint site, an artificial joint replacement at the affected joint, or a steroid injection into the same joint within the last 3 months
- You have been treated with a type of medication called a biologic therapy or a JAK inhibitor in the last 3 months, or with a medication called Rituximab in the last 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33(0)298347264
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
characterize the inflammatory infiltrate in synovial biopsies
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.